不同化疗方案治疗Ⅲ～Ⅳ期非小细胞肺癌的近期疗效观察

A Comparison of the Therapeutic Effects of Different Chemotherapy Regimens for Stage Ⅲ～Ⅳ non Small Cell Lung Cancer

摘要: 目的　观察比较MVP(丝裂霉素、长春地辛、顺铂)，MIC(丝裂霉素、异环磷酰胺、顺铂)和MNP(丝裂霉素、去甲长春碱、顺铂)联合化疗方案治疗Ⅲ～Ⅳ期非小细胞肺癌(NSCLC)的近期疗效和耐受性。方法　统计分析103例接受联合化疗的Ⅲ～Ⅳ期NSCLC，MVP组36例、MIC组30例，MNP组37例。结果　MVP组有效率30.6%，MIC组有效率33.3%、MNP组有效率48.6%，三组间疗效无显著性差异(P＞0.05)。主要毒副反应为骨髓抑制和胃肠道反应。结论　MVP、MIC和MNP方案治疗Ⅲ～Ⅳ期NSCLC疗效肯定，毒性可耐受，可以作为其一线治疗方案。

Abstract: Objective To evaluate the efficacy and toxicity of MVP(MMC+VDS+CDDP) regimen,MIC(MMC+IFO+CDDP)regimen and MNP(MMC+NVB+CDDP)regimen for stage Ⅲ～Ⅳ non-small-cell lung cancer (NSCLC). Methods The clinical data of 103 cases with stage Ⅲ～Ⅳ NSCLC were analysed.Of whom 36 cases were treated with MVP regimen,30 cases with MIC regimen,37 cases with MNP regimen. Results The result showed that respose rates of MVP,MIC and MNP regimen were 30.6% ，33.3% and 48.6% respectively.There was no statistical significant difference between them(P＞0.05).The major toxic reaction were tolerable myelo-supression and gastrointes-tinal tract reaction. Conclusion :MVP，MIC and MNP are effective and safe chemotherapy regimens and can be used as first-line regimen for treatment of stage Ⅲ～Ⅳ NSCLC Patients.